NASDAQ
38.61USD
0.00 (0.00%)
We have scored 10 news catalysts on BioLife Solutions, Inc. (BLFS) over the past 12 months. The biggest single-day move next to one of them came Mar 2, 2026, when BLFS closed −6.9%: “Wall Street Analysts Believe BioLife Solutions (BLFS) Could Rally 35%: Here's is How to Trade”. Coverage across the window leans positive (average ticker sentiment +0.21). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.9B
P/E
—
EPS
—
Beta
1.92
52W range
17.86-39.76
Day range
37.00–38.83
Open
37.16
Prev close
38.61
Volume
4.4M
Avg volume
1.1M
Dividend
0.00
IPO
1989-11-22
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BioLife Solutions, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BLFS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.
